Cargando…
S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)
Ejemplares similares
-
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
por: Pirosa, Maria Cristina, et al.
Publicado: (2022) -
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
por: Joerger, M, et al.
Publicado: (2010) -
Relapsing/refractory HL after autotransplantation: which treatment?
por: Di Renzo, Nicola, et al.
Publicado: (2020) -
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
por: Messori, A, et al.
Publicado: (2001) -
S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)
por: Ladetto, Marco, et al.
Publicado: (2023)